Drug Profile
Adecatumumab - Amgen/Merck Serono
Alternative Names: Anti-EpCAM mAb MT201; Human anti-EpCAM monoclonal antibody MT201; Monoclonal antibody MT201; MT 201; MT201 antibodyLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer Amgen; Merck Serono
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Epithelial cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Prostate cancer
Most Recent Events
- 07 Mar 2012 Micromet Inc has been acquired by Amgen
- 10 Nov 2011 Micromet completes a phase II trial in Colorectal cancer in France and Germany (NCT00866944)
- 04 Oct 2010 Adecatumumab is still in phase I trials for Breast cancer (combination therapy) in Austria and Germany